Fluoxetine potentiates GABAergic IPSCs in rat hippocampal neurons

Neuroscience Letters

Volumn 442, Issue 1, 2008, Pages 24-29

  Ye, Zeng You ^a,b   Zhou, Ke Qing ^a   Xu, Tian Le ^b   Zhou, Jiang Ning ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

5 HT; Antidepressant; GABAergic hypothesis; Neurotransmission; Whole cell patch clamp recording

Indexed keywords

BICUCULLINE; FLUOXETINE; RITANSERIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; INHIBITORY POSTSYNAPTIC POTENTIAL; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; FLUOXETINE; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; INHIBITORY POSTSYNAPTIC POTENTIALS; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 47749148056     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.06.072     Document Type: Article

References (31)

1. Amsterdam J.D., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Michelson D., Hornig-Rohan M., and Beasley C.M. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. The American Journal of Psychiatry 154 (1997) 963-969
2. Balfour D.J. Effects of GABA and diazepam on 3H-serotonin release from hippocampal synaptosomes. European Journal of Pharmacology 68 (1980) 11-16
3. Berrettini W.H., Nurnberger Jr. J.I., Hare T., Gershon E.S., and Post R.M. Plasma and CSF GABA in affective illness. British Journal of Psychiatry 141 (1982) 483-487
4. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
5. Brambilla P., Perez J., Barale F., Schettini G., and Soares J.C. GABAergic dysfunction in mood disorders. Molecular Psychiatry 8 (2003) 721-737 715
6. Derry J.M., Paulsen I.M., Davies M., and Dunn S.M. A single point mutation of the GABA(A) receptor alpha5-subunit confers fluoxetine sensitivity. Neuropharmacology 52 (2007) 497-505
7. Goren M.Z., Kucukibrahimoglu E., Berkman K., and Terzioglu B. Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochemical Research 32 (2007) 1559-1565
8. Gronli J., Fiske E., Murison R., Bjorvatn B., Sorensen E., Ursin R., and Portas C.M. Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression. Behavioural Brain Research 181 (2007) 42-51
9. Honig A., Bartlett J.R., Bouras N., and Bridges P.K. Amino acid levels in depression: a preliminary investigation. Journal of Psychiatric Research 22 (1988) 159-164
10. Karson C.N., Newton J.E., Livingston R., Jolly J.B., Cooper T.B., Sprigg J., and Komoroski R.A. Human brain fluoxetine concentrations. The Journal of Neuropsychiatry and Clinical Neurosciences 5 (1993) 322-329
11. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., and Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biological Psychiatry 17 (1982) 877-883
12. Katsurabayashi S., Kubota H., Tokutomi N., and Akaike N. A distinct distribution of functional presynaptic 5-HT receptor subtypes on GABAergic nerve terminals projecting to single hippocampal CA1 pyramidal neurons. Neuropharmacology 44 (2003) 1022-1030
13. Lloyd K.G., Zivkovic B., Scatton B., Morselli P.L., and Bartholini G. The gabaergic hypothesis of depression. Progress in Neuro-psychopharmacology & Biological Psychiatry 13 (1989) 341-351
14. Magni G., Garreau M., Orofiamma B., and Palminteri R. Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology 20 (1989) 126-131
15. McMahon L.L., and Kauer J.A. Hippocampal interneurons are excited via serotonin-gated ion channels. Journal of Neurophysiology 78 (1997) 2493-2502
16. Murase K., Ryu P.D., and Randic M. Excitatory and inhibitory amino acids and peptide-induced responses in acutely isolated rat spinal dorsal horn neurons. Neuroscience Letters 103 (1989) 56-63
17. Orsulak P.J., Kenney J.T., Debus J.R., Crowley G., and Wittman P.D. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection. Clinical Chemistry 34 (1988) 1875-1878
18. Pato M.T., Murphy D.L., and DeVane C.L. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. Journal of Clinical Psychopharmacology 11 (1991) 224-225
19. Pei Q., Zetterstrom T., and Fillenz M. Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus. Neuropharmacology 28 (1989) 1061-1066
20. Petty F. GABA and mood disorders: a brief review and hypothesis. Journal of Affective Disorders 34 (1995) 275-281
21. Petty F., and Schlesser M.A. Plasma GABA in affective illness. A preliminary investigation. Journal of Affective Disorders 3 (1981) 339-343
22. Robinson R.T., Drafts B.C., and Fisher J.L. Fluoxetine increases GABA(A) receptor activity through a novel modulatory site. The Journal of Pharmacology and Experimental Therapeutics 304 (2003) 978-984
23. Ropert N., and Guy N. Serotonin facilitates GABAergic transmission in the CA1 region of rat hippocampus in vitro. The Journal of Physiology 441 (1991) 121-136
24. Sanacora G., Fenton L.R., Fasula M.K., Rothman D.L., Levin Y., Krystal J.H., and Mason G.F. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biological Psychiatry 59 (2006) 284-286
25. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., Krystal J.H., and Mason G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 61 (2004) 705-713
26. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., and Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of General Psychiatry 56 (1999) 1043-1047
27. Sanacora G., Mason G.F., Rothman D.L., and Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. The American Journal of Psychiatry 159 (2002) 663-665
28. Shen R.Y., and Andrade R. 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. The Journal of Pharmacology and Experimental Therapeutics 285 (1998) 805-812
29. Sherman A.D., and Petty F. Additivity of neurochemical changes in learned helplessness and imipramine. Behavioral and Neural Biology 35 (1982) 344-353
30. Tunnicliff G., and Malatynska E. Central GABAergic systems and depressive illness. Neurochemical Research 28 (2003) 965-976
31. Tunnicliff G., Schindler N.L., Crites G.J., Goldenberg R., Yochum A., and Malatynska E. The GABA(A) receptor complex as a target for fluoxetine action. Neurochemical Research 24 (1999) 1271-1276